Prolaio is a foundational data layer for the cardiology segment of the AI agent ecosystem. While the company is primarily an analytics and monitoring platform, it provides the structured clinical 'ground truth' that healthcare agents require to function reliably. Its 40+ algorithms and 4 million hours of telemetry represent a specialized dataset that can inform agentic workflows in clinical decision support, patient triage, and clinical trial recruitment.

In the broader agent stack, Prolaio sits at the intersection of infrastructure and specialized applications. By synthesizing raw sensor data into FDA-cleared clinical insights, the company does the heavy lifting of data validation and labeling. This allows builders of medical agents to focus on reasoning and patient interaction rather than the underlying signal processing. Prolaio's push toward 'precision cardiology' suggests a future where agents could autonomously monitor heart health and trigger alerts based on validated medical markers rather than simple threshold violations.

The gap between daily care and clinical research

The central problem Prolaio addresses is that cardiology often remains reactive. In standard practice, a patient receives a snapshot assessment during a clinic visit, and then returns to their daily life, creating a data void until their next appointment. Prolaio attempts to fill this gap by deploying on-body sensors that generate what the company calls high-density data. According to the company, they have collected over 4 million hours of on-body patient telemetry. This information is processed through a suite of more than 40 algorithms to identify trends that manual observation or intermittent monitoring would likely miss.

By uniting patients, care teams, and researchers on a single platform, the company aims to turn real-world data into actionable clinical markers. The platform is designed to distill raw heart rate or activity data into specific insights that indicate the stability or worsening of a patient’s condition. This shift from snapshot assessments to continuous monitoring is intended to reduce the 1.3 million annual heart failure hospitalizations in the United States, many of which are considered preventable through proactive intervention.

High-density data and FDA-cleared algorithms

Prolaio emphasizes technical validation as its primary differentiator from consumer wearables. The company holds more than 20 issued patents and maintains 40 proven algorithms, five of which have received FDA clearance. This focus on regulatory approval is critical for their target users—cardiologists and pharmaceutical researchers—who require validated medical data rather than general wellness metrics. The platform uses these algorithms to analyze longitudinal data, providing a baseline of a patient's cardiovascular health that can be compared against acute changes over time.

For pharmaceutical researchers, the platform addresses the high costs and inefficiencies associated with drug development. Cardiovascular trials are historically expensive and often hampered by lost productivity or poor data quality from traditional research sites. Prolaio provides high-density data intended to optimize study design and increase confidence in clinical results. By collecting data remotely and continuously, the company helps researchers reduce the overhead of in-person monitoring while accelerating the time it takes for new treatments to reach the market.

Leadership and the Kardigan acquisition

Prolaio was co-founded by CEO Tassos Gianakakos, who previously led MyoKardia until its $13.1 billion acquisition by Bristol Myers Squibb. This background in precision medicine and biopharmaceuticals is evident in Prolaio’s focus on clinical rigor and pharmaceutical utility. The company is based in Chicago, with a leadership team that includes experts in cardiovascular medicine, data science, and product development, such as Chief Product Officer Chad Conkright and Chief Science Officer Stephan Wegerich.

In a move that consolidates its role in the health-tech stack, Kardigan acquired Prolaio. This acquisition brings Prolaio’s specialized cardiology data and monitoring capabilities into a broader ecosystem of healthcare services and pharmaceutical logistics. While the company now operates under the Kardigan umbrella, it continues to focus on the economic toll of heart disease in the U.S., which is estimated at $1 billion per day. By targeting the leading cause of death through technology-enabled care, the company seeks to move precision cardiology from a niche research field into a standard of clinical practice.